통증 관리 의약품 시장 규모, 점유율, 동향 및 예측 : 약물 종류별, 적응증, 유통 채널, 지역별(2026-2034년)

The global pain management drugs market size was valued at USD 73.04 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 90.70 Billion by 2034, exhibiting a CAGR of 2.23% from 2026-2034. North America currently dominates the market, holding a market share of 45% in 2025. The region benefits from its advanced healthcare infrastructure, comprehensive insurance coverage frameworks facilitating broad access to diverse and innovative pain therapies, a high prevalence of chronic pain conditions among its growing aging population, and substantial pharmaceutical research and development investments, all collectively reinforcing the pain management drugs market share.

The global pain management drugs market is being driven by the rising prevalence of chronic pain disorders, including arthritis, lower back pain, and neuropathic conditions, which affect a substantial portion of the global population. The increasing geriatric demographic worldwide is contributing to a higher demand for effective pain relief solutions, as older adults are more susceptible to degenerative musculoskeletal conditions and postoperative pain. Additionally, the growing burden of lifestyle-related ailments such as obesity and diabetes-related neuropathy is fueling the need for advanced analgesic therapies. Ongoing advancements in drug delivery technologies, including transdermal patches and extended-release formulations, are enhancing patient compliance and therapeutic outcomes, thereby supporting the pain management drugs market growth on a global scale.

The United States has emerged as a major region in the pain management drugs market owing to many factors. The well-developed healthcare infrastructure supports early diagnosis and treatment of pain-related conditions, while extensive insurance coverage facilitates patient access to a broad range of pain management therapies. In 2025, the U.S. Food and Drug Administration approved Journavx (suzetrigine) a first-in-class non-opioid analgesic developed by Vertex Pharmaceuticals offering a novel alternative to traditional opioids for moderate-to-severe acute pain. Furthermore, the presence of leading pharmaceutical companies and research institutions in the country fosters continuous innovation in pain management drug formulations, ensuring a robust pipeline of novel therapeutic agents aimed at improving efficacy and minimizing adverse effects for patients.

PAIN MANAGEMENT DRUGS MARKET TRENDS:

Growing Shift Toward Non-Opioid Therapies

The pharmaceutical industry is witnessing a significant transition toward non-opioid pain management therapies driven by heightened awareness of the risks associated with long-term opioid use. Healthcare providers and policymakers are prioritizing the development and adoption of safer analgesic alternatives, including nonsteroidal anti-inflammatory drugs, anticonvulsants, and novel biologics targeting specific pain pathways. According to reports, survey data following the first year of the U.S. Non-Opioids Prevent Addiction (NOPAIN) Act showed that over 80 % of hospitals and surgical centers reported decreasing perioperative opioid prescribing and increasing use of qualifying non-opioid options in pain protocols. This shift is reinforced by updated clinical guidelines that recommend non-opioid treatments as first-line options for many pain conditions, particularly chronic musculoskeletal and neuropathic pain.

Advancements in Targeted Drug Delivery

Innovations in targeted drug delivery systems are transforming the pain management drugs market outlook by enabling more precise and sustained analgesic effects while minimizing systemic side effects. Transdermal patches, liposomal formulations, and implantable drug delivery devices are gaining traction as preferred methods for administering pain medications over extended periods. In February 2025, Aveva Drug Delivery Systems launched its generic fentanyl transdermal patch in the U.S., using advanced matrix technology designed to provide consistent extended pain relief while incorporating features to deter misuse. These technologies allow for controlled release of active pharmaceutical ingredients directly to the site of pain, reducing the need for frequent dosing and improving patient adherence to treatment regimens.

Integration of Digital Health Solutions

The convergence of digital health technologies and pain management pharmacotherapy is reshaping treatment paradigms and influencing the pain management drugs market trends across the globe. Mobile health applications and wearable devices are being integrated with pharmaceutical interventions to provide comprehensive pain monitoring and management solutions. These digital tools enable healthcare providers to track patient pain levels, medication usage patterns, and treatment outcomes in real time, facilitating data-driven adjustments to therapeutic regimens. In September 2025, Pier 88 Health and Theranica received regulatory approval in China for the Nerivio(R) REN wearable device, a prescribed digital therapeutic for migraine that exemplifies how digital pain technologies are gaining global clinical acceptance beyond traditional drug therapy. Telemedicine platforms are expanding access to pain specialists in underserved regions, improving diagnosis and prescription accuracy for patients with complex pain conditions.

PAIN MANAGEMENT DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

• NSAIDs
• Anesthetics
• Anticonvulsants
• Antimigraine Agents
• Antidepressants
• Opioids
• Others

Opioids currently occupy a market share of 35%, which is a prominent category in pain management. Opioids are prescribed for moderate to severe pain conditions, such as postoperative pain, cancer pain, and advanced musculoskeletal diseases. Opioids work by interacting with opioid receptors in the central and peripheral nervous system, thus modulating pain perception. The use of opioids in the healthcare setting continues to be high due to their proven efficacy in the management of acute and chronic pain that is unresponsive to non-opioid options. Long-acting and abuse-deterrent formulations of opioids have been introduced to mitigate concerns about opioid abuse while still providing therapeutic benefits to patients who require chronic pain management. Healthcare professionals are increasingly turning to multimodal therapy that combines opioids with other treatments to provide improved pain relief while minimizing opioid use. Guidelines for opioid prescription continue to be refined to ensure prudent use while providing patients with access to pain management options.

Analysis by Indication:

• Musculoskeletal Pain
• Surgical and Trauma Pain
• Cancer Pain
• Neuropathic Pain
• Migraine Pain
• Obstetrical Pain
• Fibromyalgia Pain
• Burn Pain
• Dental/Facial Pain
• Pediatric Pain
• Others

Musculoskeletal pain leads the market with a share of 38%. Musculoskeletal pain encompasses a broad spectrum of conditions affecting bones, joints, muscles, tendons, and ligaments, making it one of the most prevalent pain categories globally. The high demand for medications targeting musculoskeletal pain is driven by the increasing incidence of osteoarthritis, rheumatoid arthritis, lower back pain, and sports-related injuries across diverse demographic groups. Aging populations worldwide are particularly susceptible to degenerative joint diseases and spinal disorders, sustaining consistent demand for effective pharmacological interventions. Treatment protocols for musculoskeletal pain typically involve nonsteroidal anti-inflammatory drugs, muscle relaxants, corticosteroids, and topical analgesics, with biologic therapies gaining prominence for refractory cases. The rising adoption of combination therapies and the development of disease-modifying agents are positively influencing the pain management drugs market forecast for this indication. Rehabilitation-focused treatment strategies that integrate pharmacotherapy with physical therapy are becoming standard practice, enhancing overall patient outcomes and driving sustained demand for targeted musculoskeletal pain medications.

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hospital pharmacies account for the largest market share of 55%, as they are the main distribution channel for pain management medications due to their direct link with the healthcare system. These pharmacies handle the distribution of controlled medications such as opioids and anesthetics. They are regulated by the relevant authorities to ensure that patients receive the medication correctly. The main reason for the large market share of hospital pharmacies is that they play a crucial role in the management of acute pain, surgical pain, and pain resulting from chronic illnesses. The hospital pharmacists work in collaboration with pain management teams to ensure that the drug selection and monitoring programs are optimized for individual patients. The rising number of surgeries, trauma cases, and cancer treatments in hospitals continues to drive the market through this distribution channel. The hospital pharmacies also handle formulary and bulk purchases that affect prescribing practices and ensure that patients have access to a wide range of analgesic medications at an affordable cost.

Regional Analysis:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

North America, with a market share of 45%, retaining the leading market position. The region enjoys a well-developed healthcare infrastructure with a strong focus on sophisticated diagnostic facilities, comprehensive insurance coverage, and universal access to both primary and specialty pain management care. The large number of patients with chronic pain conditions such as lower back pain, arthritis, and neuropathies in the region supports strong demand for various analgesic treatments. Well-developed pharmaceutical research infrastructure and the presence of major pharmaceutical companies in the region have helped to ensure steady innovation in pain management products, such as abuse-deterrent opioid formulations and new non-opioid modalities. Government policies to counter opioid abuse have spurred the development and launch of safer pain management products, promoting the concept of multimodal pain management. Reimbursement-friendly policies and government-sponsored pain management programs have also helped to ensure better accessibility to prescription pain management products in the region.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The United States represents a significant contributor to the pain management drugs market within North America, supported by the high prevalence of chronic and acute pain conditions across the population. The country possesses a well-established pharmaceutical ecosystem with robust research and development capabilities focused on developing next-generation analgesic therapies. In August 2025, the U.S. FDA approved Tonmya a non-opioid treatment for fibromyalgia-related pain, marking the first new therapy for this chronic pain condition in over 15 years and expanding patient options beyond traditional drugs. Healthcare providers are increasingly adopting evidence-based pain management protocols that integrate pharmacological treatments with complementary and alternative approaches, reflecting the evolving clinical landscape. The regulatory environment has shifted toward encouraging non-opioid alternatives, with expedited approval pathways for novel pain therapeutics that demonstrate improved safety profiles. The growing emphasis on personalized medicine is driving the development of genetic testing tools that help clinicians identify optimal pain medications for individual patients, reducing trial-and-error prescribing. Additionally, the expansion of outpatient pain management clinics and ambulatory surgical centers is diversifying drug distribution channels and improving access for patients in rural and underserved communities.

EUROPE PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The European market for pain management drugs is driven by a complex regulatory environment and well-established national healthcare systems that ensure widespread patient access to analgesic treatments. The region has a large burden of chronic pain disorders such as osteoarthritis, rheumatoid arthritis, and cancer pain, which continues to fuel demand for effective pharmacologic therapies. The European regulatory bodies have established tough guidelines for the use of opioids, thus encouraging the use of non-opioid alternatives and multimodal approaches to pain management. The focus on value-based healthcare in the major European economies is shaping formulary inclusion and encouraging the use of cost-effective generic analgesics in combination with innovative branded therapies. Research organizations and pharmaceutical companies in the region are working together on clinical trials for new pain therapies, including biologic and gene therapies that target specific pain pathways. In addition, the aging population in Western European nations is fueling the burden of degenerative musculoskeletal disorders, thus sustaining demand for long-term pain management strategies and rehabilitation pharmacotherapy.

ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Asia-Pacific pain management drugs market is experiencing significant expansion driven by improving healthcare infrastructure, growing awareness of pain management options, and increasing healthcare expenditure across developing economies. The large and aging population base in countries throughout the region contributes to a rising burden of chronic pain conditions, including osteoarthritis, diabetic neuropathy, and cancer-related pain. Government initiatives aimed at expanding universal health coverage and improving access to essential medications are supporting increased utilization of analgesic therapies. The growing middle-class population with enhanced purchasing power is driving demand for advanced branded pain medications in addition to affordable generic alternatives. The region is also witnessing increased investment in pharmaceutical manufacturing capabilities, enabling local production of pain management drugs and reducing dependence on imports.

LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Latin American pain management drugs market is expanding as healthcare infrastructure development progresses across the region, improving access to diagnostic and therapeutic services for pain management. The growing burden of chronic diseases, including diabetes and cardiovascular conditions, is increasing the prevalence of associated pain disorders that require pharmacological intervention. Government healthcare reforms aimed at expanding medication coverage and reducing out-of-pocket expenses are supporting broader patient access to analgesic therapies. The increasing urbanization across the region is facilitating greater awareness of pain treatment options and improving distribution networks for pharmaceutical products. Local generic drug manufacturers are playing a vital role in expanding access.

MIDDLE EAST AND AFRICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Middle East and Africa pain management drugs market is developing steadily as regional healthcare systems undergo modernization and expansion. Growing government investment in healthcare infrastructure is improving access to pain management services, particularly in urban centers across the region. The increasing prevalence of chronic pain conditions linked to lifestyle changes, aging demographics, and road traffic injuries is driving demand for analgesic medications. International pharmaceutical companies are expanding their presence in the region through strategic partnerships with local distributors. Regulatory frameworks governing controlled substance distribution are evolving, facilitating safer and broader access to essential pain management medications for underserved populations.

COMPETITIVE LANDSCAPE:

The pain management drugs market is characterized by intense competition among established pharmaceutical companies, generic drug manufacturers, and emerging biotechnology firms. Major market players are focusing on expanding their product portfolios through the development of novel analgesic formulations, including abuse-deterrent opioids, non-opioid alternatives, and targeted biologic therapies. Strategic initiatives such as mergers, acquisitions, and licensing agreements are being pursued to strengthen market positions and gain access to innovative drug delivery technologies. Companies are investing heavily in clinical research to advance pipeline candidates through regulatory approval processes, with particular emphasis on drugs addressing unmet medical needs in chronic and neuropathic pain management. Competitive differentiation is being achieved through the development of extended-release formulations, combination therapies, and patient-centric drug delivery systems.

The report provides a comprehensive analysis of the competitive landscape in the pain management drugs market with detailed profiles of all major companies, including:

• Abbott Laboratories Inc.
• AbbVie Inc.
• Bausch + Lomb.
• Bayer AG
• Eli Lilly & Company
• GSK plc
• Pfizer Inc.
• Purdue Pharma L.P.
• Sanofi S.A
• Viatris Inc

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the pain management drugs market?

2. What is the future outlook of the pain management drugs market?

3. What are the key factors driving the pain management drugs market?

4. Which region accounts for the largest pain management drugs market share?

5. Which are the leading companies in the global pain management drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pain Management Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Drug Class
• 5.5 Market Breakup by Indication
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Drug Class

• 6.1 NSAIDs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Anesthetics
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Anticonvulsants
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Antimigraine Agents
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Antidepressants
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Opioids
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Musculoskeletal Pain
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Surgical and Trauma Pain
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cancer Pain
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Neuropathic Pain
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Migraine Pain
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Obstetrical Pain
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Fibromyalgia Pain
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Burn Pain
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast
• 7.9 Dental/Facial Pain
  • 7.9.1 Market Trends
  • 7.9.2 Market Forecast
• 7.10 Pediatric Pain
  • 7.10.1 Market Trends
  • 7.10.2 Market Forecast
• 7.11 Others
  • 7.11.1 Market Trends
  • 7.11.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Europe
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Asia Pacific
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Middle East and Africa
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Latin America
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories Inc.
  • 14.3.2 AbbVie Inc.
  • 14.3.3 Bausch + Lomb.
  • 14.3.4 Bayer AG
  • 14.3.5 Eli Lilly & Company
  • 14.3.6 GSK plc
  • 14.3.7 Pfizer Inc.
  • 14.3.8 Purdue Pharma L.P.
  • 14.3.9 Sanofi S.A
  • 14.3.10 Viatris Inc